Lingohr Asset Management GmbH Cuts Holdings in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Lingohr Asset Management GmbH significantly decreased its holdings in Jazz Pharmaceuticals, reducing its position by 94% during the second quarter, now owning only 2,395 shares valued at approximately $254,000.
• Other institutional investors have shown mixed movements; notable changes include Nuveen LLC acquiring a new position valued at about $62.36 million and Goldman Sachs increasing its stake by 147.7%.
• Jazz Pharmaceuticals reported a net loss of ($8.25) EPS for the last quarter, missing estimates, while its revenue was stable at $1.05 billion, reflecting a year-over-year growth of 2.1%.

Lingohr Asset Management GmbH cut its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 94.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,395 shares of the specialty pharmaceutical company's stock after selling 37,288 shares during the quarter. Lingohr Asset Management GmbH's holdings in Jazz Pharmaceuticals were worth $254,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JAZZ. Nuveen LLC purchased a new position in Jazz Pharmaceuticals during the first quarter worth about $62,362,000. Fuller & Thaler Asset Management Inc. boosted its stake in Jazz Pharmaceuticals by 41.7% in the first quarter. Fuller & Thaler Asset Management Inc. now owns 1,331,011 shares of the specialty pharmaceutical company's stock valued at $165,245,000 after acquiring an additional 391,660 shares during the last quarter. Perpetual Ltd boosted its stake in Jazz Pharmaceuticals by 60.2% in the first quarter. Perpetual Ltd now owns 952,172 shares of the specialty pharmaceutical company's stock valued at $118,212,000 after acquiring an additional 357,784 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Jazz Pharmaceuticals by 14.4% in the first quarter. Dimensional Fund Advisors LP now owns 2,328,430 shares of the specialty pharmaceutical company's stock valued at $289,066,000 after acquiring an additional 293,360 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in Jazz Pharmaceuticals by 147.7% in the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company's stock valued at $43,652,000 after acquiring an additional 209,667 shares during the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $126.16 on Monday. The company's 50 day moving average is $118.59 and its 200-day moving average is $116.35. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. The firm has a market cap of $7.65 billion, a P/E ratio of -18.75, a price-to-earnings-growth ratio of 7.82 and a beta of 0.24.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The business had revenue of $1.05 billion during the quarter, compared to the consensus estimate of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The business's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the firm earned $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on JAZZ. The Goldman Sachs Group boosted their target price on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research note on Friday, August 29th. Royal Bank Of Canada boosted their target price on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a research note on Thursday, August 28th. Deutsche Bank Aktiengesellschaft began coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a "buy" rating and a $152.00 target price on the stock. Zacks Research upgraded shares of Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Friday, August 15th. Finally, Morgan Stanley boosted their price target on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. Fourteen investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $178.67.

Insiders Place Their Bets

In related news, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total transaction of $771,720.00. Following the sale, the director owned 429,973 shares of the company's stock, valued at approximately $55,303,127.26. This represents a 1.38% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.